News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel

Panel: Understanding the Strategic Consequences of FDA’s Proposed Down‑Classification of IVD Tests from Class III to Class II and Its Impact on Regulatory Pathways, Market Access Innovation and Clinical Laboratory Practice

To access this post, you must purchase Executive War College 2026 – Audio Recordings.

;